JCB, Volume 11, Number 4, 2005 Editorial Vol.11 No. 4 (2005) Editorial: Moving beyond metaphors: University-industry collaboration in biotechnology Michael J Lynskey   Article Vol.11 No. 4 (2005) Commercialisation and spin-out activities of the Institute of Biotechnology Christopher R Lowe Knowledge is now recognised as a prime driver of innovation, productivity and economic growth. The new economies will require heavy investment into research and develop Article Vol.11 No. 4 (2005) Stanford's licensing and equity practices with biotechnology companies Kirsten Leute Stanford University's Office of Technology Licensing (OTL) has a long history of licensing technologies to biotechnology start-up companies. This paper presents (1) exa Article Vol.11 No. 4 (2005) How DanioLabs has evolved its relationship with the CIMR Paul Goldsmith The commonest interaction of industry with academia is as the passive recipient of intellectual property. A much deeper and productive interaction is possible with the Article Vol.11 No. 4 (2005) The role of research institutions in the formation of the biotech cluster in Massachusetts: The MIT experience Lita L Nelsen Based on the MIT experience and that of other US universities, the formation and sustained existence of biotechnology company clusters are discussed. A cluster's origin Article Vol.11 No. 4 (2005) The evolving concept of value add in university commercialisation Alison F Campbell Universities have been challenged to assess what value creation means to them against a complex backdrop of changing markets and funding priorities. In response, univer Article Vol.11 No. 4 (2005) Current topics in biotechnology patent law: The written description requirement Benjamin A Adler Universities and medical research institutions are as interested in securing patent protection for their biotechnological inventions as pharmaceutical and biotechnology Article Vol.11 No. 4 (2005) How academics can make (extra) money out of their science William Bains This paper analyses how UK academics can make money from their expertise, other than through earning their salary. Using statistics from the success rate and likely rem Article Vol.11 No. 4 (2005) Kinik: Raising the stakes for importing products derived from US patented processes practised abroad Scott B Familant This paper analyses the recent ruling in Kinik Co. v. Int'l Trade Comm'n, 362 F.3d 1359 (Fed. Cir. 2004), and the impact that decision may have on proceedings b Article Vol.11 No. 4 (2005) Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004 Mark J Belsey As part of Datamonitor's alliance and licensing strategic analysis, the authors have completed a two year survey of the trends underlying early-stage drug discovery and Legal and Regulatory Updates Vol.11 No. 4 (2005) Legal and regulatory update John Wilkinson The Human Tissue Act received royal assent on 15th November, 2004, but its provisions will not come into force until the Secretary of State makes relevant orders by sta Legal and Regulatory Updates Vol.11 No. 4 (2005) Financial accounts reports Colin Aaronson Basilea Pharmaceutica AG is a Swiss-based biotechnology company whose shares are traded on the Swiss Stock Exchange. It is developing antibacterial and antifungal drugs